Losartan Potassium CAS 124750-99-8 API Factory Antihypertensive High Purity
Supply Losartan Potassium and Related Intermediates with High Quality
Losartan Potassium CAS 124750-99-8
2-Butyl-4-Chloro-5-Formylimidazole (BCFI) CAS 83857-96-9
| Chemical Name | Losartan Potassium |
| Synonyms | DuP 753; Cozaar; 2-Butyl-4-chloro-1-[[2'-(1H-tetrazol-5-yl)-1,1'-biphenyl-4-yl]methyl]imidazole-5-methanol Potassium Salt |
| CAS Number | 124750-99-8 |
| CAT Number | RF-API98 |
| Stock Status | In Stock, Production Scale Up to Tons |
| Molecular Formula | C22H22ClKN6O |
| Molecular Weight | 461.01 |
| Melting Point | 263.0~265.0℃ |
| Solubility | Freely Soluble in Water and in Methanol, Slightly Soluble in Acetonitrile. |
| Brand | Ruifu Chemical |
| Item | Specifications |
| Appearance | White or Almost White Crystalline Powder |
| Identification A | Infrared Absorption: Must Similar to Reference Standard |
| Identification B | Ultraviolet absorption: Must Similar to Reference Standard |
| Test for Potassium | Must be Positive |
| Water Content (K.F) | ≤0.50% |
| Heavy Metals | ≤10ppm |
| Related Substances (HPLC) | |
| Any Individual Impurity | ≤0.20% |
| Total Impurities | ≤0.50% |
| Residual Solvents (GC) | |
| Cyclohexane | ≤0.10% |
| Isopropyl Alcohol | ≤0.20% |
| Assay/Analysis Method | 98.5~101.0% (HPLC, calculated on anhydrous, solvent-free basis) |
| N-Nitrosodiethylamine | ≤0.177ppm (NDEA) |
| N-Nitrosodimethylamine | ≤0.640ppm (NDMS) |
| Particle Size | 90% Less Than 38 Microns |
| Shelf Life | 24 Months |
| Test Standard | Enterprise Standard |
| Usage | API, Angiotensin II Receptor Antagonist Antihypertensive |
Package: Bottle, Aluminum foil bag, Cardboard drum, 25kg/Drum, or according to customer's requirement.
Storage Condition: Store in sealed containers at cool and dry place; Protect from light, moisture and pest infestation.
Losartan Potassium is the first potent and selective non-peptide angiotensin II receptor type 1 (AT1) antagonist introduced to the market as a once-daily oral antihypertensive. The concentration that inhibits 50% of the binding of angiotensin II (IC50) is 20 nM. Losartan (40 μM) affects ISC but prevents the effect of ANGII on ISC. Losartan significantly reduces Ang II-mediated cell proliferation in endometrial cancer cells. The combination of losartan and anti-miR-155 has a significantly greater antiproliferative effect compared to each drug alone. It is metabolized to produce the 5-carboxylic acid metabolite (EXP3174) and is reported to lower blood pressure. It is currently being researched as a potential treatment for COVID-19 for its potential to mitigate or possibly attenuate the symptoms of COVID-19.
1. For the treatment of essential hypertension, it can be used alone or in combination with other antihypertensive drugs (such as diuretics). 2. For the treatment of heart failure, it can be used alone or in combination with cardiotonic or diuretic Chemicalbook drugs. 3. Preventing stroke in patients with hypertension and left ventricular hypertrophy. 4. It is used to slow the progression of nephropathy in patients with type 2 diabetes associated with nephropathy and hypertension.
